⚕ GalenOps field
←

SITE014-0161

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-09-15

AEs
6
Serious
1
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-10-15 (study day 24); relationship: not assessed

severe assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-13 (study day 53); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-17 (study day 57); relationship: N

severe serious assessed

Grade 3 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-21 (study day 61); relationship: not assessed; serious criteria: hospitalization

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-28 (study day 68); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-01 (study day 71); relationship: not assessed

Data queries

No data queries.